These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 27924751)

  • 1. Neurological sequelae of cancer immunotherapies and targeted therapies.
    Wick W; Hertenstein A; Platten M
    Lancet Oncol; 2016 Dec; 17(12):e529-e541. PubMed ID: 27924751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Critical Care Management of Toxicities Associated With Targeted Agents and Immunotherapies for Cancer.
    Gutierrez C; McEvoy C; Munshi L; Stephens RS; Detsky ME; Nates JL; Pastores SM
    Crit Care Med; 2020 Jan; 48(1):10-21. PubMed ID: 31725440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The double-edged sword: Neurotoxicity of chemotherapy.
    Magge RS; DeAngelis LM
    Blood Rev; 2015 Mar; 29(2):93-100. PubMed ID: 25445718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology.
    Grávalos C; Sanmartín O; Gúrpide A; España A; Majem M; Suh Oh HJ; Aragón I; Segura S; Beato C; Botella R
    Clin Transl Oncol; 2019 May; 21(5):556-571. PubMed ID: 30284232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurological Complications of the Treatment of Pediatric Neoplastic Disorders.
    Sun LR; Cooper S
    Pediatr Neurol; 2018 Aug; 85():33-42. PubMed ID: 30126755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurologic Toxicities of Cancer Immunotherapies: a Review.
    Harrison RA; Tummala S; de Groot J
    Curr Neurol Neurosci Rep; 2020 Jun; 20(7):27. PubMed ID: 32514633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Central nervous system complications of cancer therapy.
    Rinne ML; Lee EQ; Wen PY
    J Support Oncol; 2012; 10(4):133-41. PubMed ID: 22542045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurological toxicities associated with immune-checkpoint inhibitors.
    Touat M; Talmasov D; Ricard D; Psimaras D
    Curr Opin Neurol; 2017 Dec; 30(6):659-668. PubMed ID: 28938341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cutaneous adverse effects of targeted therapies: Part II: Inhibitors of intracellular molecular signaling pathways.
    Macdonald JB; Macdonald B; Golitz LE; LoRusso P; Sekulic A
    J Am Acad Dermatol; 2015 Feb; 72(2):221-36; quiz 237-8. PubMed ID: 25592339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurological complications of immune checkpoint inhibitor cancer immunotherapy.
    Zivelonghi C; Zekeridou A
    J Neurol Sci; 2021 May; 424():117424. PubMed ID: 33812689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Smallpox vaccination and adverse reactions. Guidance for clinicians.
    Cono J; Casey CG; Bell DM;
    MMWR Recomm Rep; 2003 Feb; 52(RR-4):1-28. PubMed ID: 12617510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse Events in Cancer Immunotherapy.
    Abdel-Wahab N; Alshawa A; Suarez-Almazor ME
    Adv Exp Med Biol; 2017; 995():155-174. PubMed ID: 28321817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paraneoplastic Neurological Syndromes and Beyond Emerging With the Introduction of Immune Checkpoint Inhibitor Cancer Immunotherapy.
    Valencia-Sanchez C; Zekeridou A
    Front Neurol; 2021; 12():642800. PubMed ID: 33897597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune-related adverse events with immune checkpoint blockade: a comprehensive review.
    Michot JM; Bigenwald C; Champiat S; Collins M; Carbonnel F; Postel-Vinay S; Berdelou A; Varga A; Bahleda R; Hollebecque A; Massard C; Fuerea A; Ribrag V; Gazzah A; Armand JP; Amellal N; Angevin E; Noel N; Boutros C; Mateus C; Robert C; Soria JC; Marabelle A; Lambotte O
    Eur J Cancer; 2016 Feb; 54():139-148. PubMed ID: 26765102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurologic Complications of Cancer Therapies.
    Lee EQ
    Curr Neurol Neurosci Rep; 2021 Nov; 21(12):66. PubMed ID: 34817688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Management of Toxicities of Immune Checkpoint Inhibitors].
    Horio Y
    Gan To Kagaku Ryoho; 2017 Mar; 44(3):185-190. PubMed ID: 28292987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Central nervous system injury from novel cancer immunotherapies.
    Winter SF; Vaios EJ; Dietrich J
    Curr Opin Neurol; 2020 Dec; 33(6):723-735. PubMed ID: 32941192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Radiotherapy and New Cancer Drugs - New Side Effects ?].
    Nakamura S
    Gan To Kagaku Ryoho; 2018 Mar; 45(3):424-427. PubMed ID: 29650897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Rituximab (anti-CD20) in neurological disorders].
    Akaishi T; Nakashima I
    Brain Nerve; 2014 Oct; 66(10):1167-78. PubMed ID: 25296871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dermatologic Adverse Events of Systemic Anticancer Therapies: Cytotoxic Chemotherapy, Targeted Therapy, and Immunotherapy.
    Deutsch A; Leboeuf NR; Lacouture ME; McLellan BN
    Am Soc Clin Oncol Educ Book; 2020 May; 40():485-500. PubMed ID: 32421446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.